Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cancer pharmacogenomics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    124 result(s) found for: Cancer pharmacogenomics. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2006-004016-40 Sponsor Protocol Number: 13570 Start Date*: 2006-11-09
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
    Full Title: APPLICATION OF PHARMACOGENOMICS IN THE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED COLORECTAL CANCER
    Medical condition: ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER
    Disease: Version SOC Term Classification Code Term Level
    6.1 10010040 HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000095-28 Sponsor Protocol Number: H3E-MC-JMHW Start Date*: 2017-03-02
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase II Study of Pemetrexed in Children with Recurrent Malignancies
    Medical condition: Recurrent Malignancies (recurrent solid tumors): Target tumor types were osteosarcoma, Ewing sarcoma/peripheral PNET, rhabdomyosarcoma, neuroblastoma (measurable disease), neuroblastoma (metaiodob...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-000586-19 Sponsor Protocol Number: 307971 Start Date*: 2005-07-25
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC)
    Medical condition: Non small cell lung cancer (NSCLC) stage IIIB or stage IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004321-83 Sponsor Protocol Number: GEFCAPI04 Start Date*: 2014-01-27
    Sponsor Name:Institut Català d'Oncologia (ICO)
    Full Title: A randomised phase III trial comparing a strategy based on molecular analysis to the empiric strategy in patients with carcinoma of an unknoun primary (CUP)
    Medical condition: Carcinomas of an unknown primary site (CUP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002808-28 Sponsor Protocol Number: OZM-061 Start Date*: 2017-12-29
    Sponsor Name:Princess Margaret Cancer Centre
    Full Title: Olala Trial: A Retrospective/Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours
    Medical condition: epithelial ovarian cancer (including fallopian tube or peritoneal cancer)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000548-25 Sponsor Protocol Number: PM1183-B-004-13 Start Date*: 2013-06-11
    Sponsor Name:Pharma Mar S.A. Sociedad Unipersonal
    Full Title: A Randomized-Controlled Three-arm Phase II Study of Lurbinectedin (PM01183) Alone or In Combination with Gemcitabine and a control arm with Docetaxel as Second-Line Treatment in Unresectable Non-Sm...
    Medical condition: Unresectable Non-Small Cell Lung Cancer (NSCLC).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-005276-16 Sponsor Protocol Number: ET743-OVA-301 Start Date*: 2005-10-27
    Sponsor Name:Pharma Mar S.A.
    Full Title: An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer.
    Medical condition: Advanced relapsed ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005251-39 Sponsor Protocol Number: PM1183-C-004-14 Start Date*: 2015-06-15
    Sponsor Name:Pharma Mar S.A., Sociedad Unipersonal
    Full Title: Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial)
    Medical condition: Platinum-resistant ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033130 Ovarian cancer NOS LLT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) ES (Completed) CZ (Completed) AT (Completed) BE (Completed) GB (Completed) FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000879-26 Sponsor Protocol Number: 311602-Amendment 1 Start Date*: 2008-08-07
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: (REASON) double-blind, Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy.
    Medical condition: - Advanced refractory or relapsed ovarian cancer - Patients with metastatic hormone-refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    9.1 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) BE (Completed) GB (Completed) DE (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000120-33 Sponsor Protocol Number: C-550-01 Start Date*: 2018-11-19
    Sponsor Name:Agenus Inc.,
    Full Title: A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with AGEN2034 in Subjects with Metas...
    Medical condition: Phase 1 – Part A dose escalation in patients with locally advanced, recurrent and/or metastatic solid tumor for which no standard therapy exists or standard therapy has failed. Phase 2 - Part B adv...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008236 Cervical cancer stage IV LLT
    21.1 100000004864 10008231 Cervical cancer recurrent LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005661-11 Sponsor Protocol Number: XELOXART Start Date*: 2006-03-30
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: PHASE II STUDY OF NEOADJUVANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER
    Medical condition: rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10062099 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000992-28 Sponsor Protocol Number: KCT04/2015-DORETAonko/SI Start Date*: 2015-07-15
    Sponsor Name:Krka, d.d., Novo mesto
    Full Title: A comparison of the severity of acute pain and the frequency of chronic pain after post-operative analgesia of lower and higher intensity following surgical emptying of the axillary gland in breast...
    Medical condition: Acute pain after surgical emptying of the axillary gland in breast cancer patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10018065 - General disorders and administration site conditions 10033371 Pain PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001552-44 Sponsor Protocol Number: TRIO 015 Start Date*: 2008-09-29
    Sponsor Name:Cancer International research Group
    Full Title: A MULTICENTER OPEN LABEL PHASE II STUDY OF THE EFFICACY AND SAFETY OF AMG 479, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST INSULIN-LIKE GROWTH FACTOR TYPE 1 RECEPTOR (IGF-1R) AS SECOND LINE THERAPY I...
    Medical condition: Recurrent Platinum-sensitive ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) DE (Completed) ES (Prematurely Ended) IE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006413-33 Sponsor Protocol Number: 3206K2-104-WW Start Date*: 2008-02-14
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: A Phase 1/2 Dose Escalation Study of TRU-015 in Subjects with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
    Medical condition: Relapsed or refractory B-cell Non Hodgkin's Lymphoma.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001551-22 Sponsor Protocol Number: TRIO 014 Start Date*: 2008-10-21
    Sponsor Name:Cancer International Research Group
    Full Title: A randomized, double-blind, placebo controlled, multicenter, phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) to first...
    Medical condition: Optimally debulked epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022163-35 Sponsor Protocol Number: EFC11785 Start Date*: 2011-04-04
    Sponsor Name:sanofi-aventis R&D
    Full Title: Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostat...
    Medical condition: metastatic Castration Resistant Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) HU (Completed) BE (Completed) ES (Completed) GB (Completed) FR (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-016846-16 Sponsor Protocol Number: OCTO-16 Start Date*: 2010-12-14
    Sponsor Name:University of Oxford
    Full Title: Phase II Clinical Trial of 6-Mercaptopurine(6MP)and low-dose Methotrexate In Patients With Known BRCA Defective Tumours.
    Medical condition: Advanced or metastatic breast or ovarian cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028985 Neoplasm breast LLT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000015-25 Sponsor Protocol Number: 3066A1-303-WW Start Date*: 2004-07-16
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
    Full Title: A phase 3 randomized, placebo-controlled, double-blind study of oral CCI-779 administered in combination with letrozole vs. letrozole alone as first line hormonal therapy in postmenopausal women wi...
    Medical condition: locally advanced or metastatic breast cancer (stage 3B or 4)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Completed) LV (Completed) LT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022064-12 Sponsor Protocol Number: EFC11784 Start Date*: 2011-03-23
    Sponsor Name:sanofi-aventis R&D
    Full Title: Randomized, Open Label, Multi-Center Study comparing Cabazitaxel at 25 mg/m2 and at 20 mg/m² in Combination with Prednisone Every 3 Weeks to Docetaxel in Combination with Prednisone in Patients wit...
    Medical condition: metastatic Castration Resistant Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) CZ (Completed) ES (Completed) FI (Completed) DK (Completed) PT (Completed) IT (Completed) DE (Completed) RO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002534-23 Sponsor Protocol Number: 3124001 Start Date*: 2018-02-08
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: SAFETY AND PHARMACOKINETICS OF ODM-208 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Medical condition: Metastatic castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Trial now transitioned) FR (Trial now transitioned) GB (Temporarily Halted)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 01:45:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA